Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
161Tb-RAD402 in Castration-Resistant Prostate Cancer
NCT07259213Phase 2Recruiting
- Sponsor
- Radiopharm Theranostics
- Start
- Mar 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of RAD 402 in castration-resistant prostate cancer (CRPC), sponsored by Radiopharm Theranostics. Started Mar 2026; status: recruiting.
02
Drugs
RAD 402
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07259213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259213.